Biographies

PETER STENVINKEL

Peter Stenvinkel serves as a professor and senior lecturer at Dept. of Renal Medicine Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden.

He has published about 570 original publications and reviews and 30 book chapters on various aspects of inflammation, wasting and metabolism in chronic kidney disease patients.
His Hirsch index is 86 according to PubMed and 109 according to Google Schoolar. He has given more than 400 invited lectures at various international meetings and congresses in about 30 different countries.

He has received prize for the best Swedish thesis in diabetology 1994 and was a Baxter Extramural Grant awardee 1996. He was a Karolina Price awardee 2005 and a Vizenca price awardee 2009. He received the Addis Gold medal by the ISRNM for nutritional research 2010.

He is a member of the council of International Society of Nephrology (2007-) and ERA-EDTA (2007-2010). He is an associate Editor of NDT and was editor-in-chief on NDT-E 2010-2013. He received an honorary membership of the Australian and New Zealand Society of Nephrology 2010 and of the Polish Society of Nephrology in 2012. He was an international NKF awardee 2012. He is a fellow of ERA-EDTA and ASN.

PER-HENRIK GROOP

Professor Per-Henrik Groop, MD, DMSc, FRCPE graduated from the University of Helsinki in 1982. It was here where he defended his thesis on ‘The relationship between GIP and beta-cell function in man’ in 1989. Following post-doctoral studies at Guy’s Hospital, University of London, under Professor Giancarlo Viberti, Professor Groop returned to Helsinki as Consultant of Nephrology. He served as Professor of Nephrology (Chair) 2010-2015 and is currently Professor of Internal Medicine (Chair) at the University of Helsinki. He is also Chief Physician at the Abdominal Center Nephrology, University of Helsinki and Helsinki University Hospital and Principal Investigator of the Finnish Diabetic Nephropathy (FinnDiane) Study at the Folkhälsan Research Center in Helsinki, Finland. He is Adjunct Professor at the Department of Diabetes, Monash University, Melbourne, Australia.

His research is focused on the dissection of the pathogenesis of diabetic complications with special emphasis on diabetic nephropathy. In order to provide a unique set of clinical resources with high power to identify genes and genetic variants associated with diabetic complications, Professor Groop initiated the large, nationwide FinnDiane Study in 1997. To date, this landmark study comprises 8400 patients with Type 1 Diabetes and their family members recruited via a comprehensive network of 92 hospitals and healthcare centres throughout Finland. His FinnDiane Research Group represents an inter-disciplinary team of 45 scientists, post-graduate students and personnel.

Professor Groop served as Associate Editor of Diabetologia, 2005–2007, and as member of the Advisory Board, 2008–2011. He served as Associate Editor of Kidney International and International Diabetes Monitor, 2007–2011. He was Chairman of the EASD Scientist Training Course, 2007–2013, President of the European Diabetic Nephropathy Study Group (EDNSG), 2008–2010, and Honorary Secretary of the EASD 2013-2016. He is since 2011 the chairman of the Signe and Ane Gyllenberg Foundation. He was awarded the prestigious EASD Castelli Pedroli Prize – 24th Camillo Golgi Lecture in 2009, the Novo Nordisk Foundation Lecture in 2012 and the IDF Award for Clinical and Therapeutic Research 2019.

Professor Groop has published more than 390 peer-reviewed original articles in high-impact journals, 35 reviews and book chapters, 49 papers in his native languages Swedish and Finnish as well as more than 640 abstracts presented at major international meetings.

SAM EL-OSTA

Professor Sam El-Osta is a Senior Research Fellow with the National Health & Medical Research Council of Australia, and Head of the Epigenetics in Human Health and Disease Laboratory and Professor of Medicine, Monash University.

He has contributed more than 200 articles and publishes research that is highly influential in the field of transcription and chromatin biology. In recognition of his research into epigenetics, he was awarded AMGEN Australian Medical Researcher of the Year in 2006 by the ASMR Australian Society for Medical Research.
The inclusion of his prominent research into the Faculty of 1000 Biology and Nature Milestones as well as most read articles in Circulation Research “honor roll” for 2011 exemplify an authoritative position, influence, and international reputation.

While frequently invited to write editorials, his research is recognized in editorials and was awarded in the “2013 Anthology” of most significant science in Circulation Research. He was recently elected vice-president of the International Epigenetics Society and serve as guest editor and solicited to contribute authoritative reviews for prominent journals that in 2015/16 include Antioxidants & Redox Signaling, Cellular and Molecular Life Sciences, Molecular Aspects of Medicine and Circulation Research.

As well as his promotion to Professor in 2013 and in recognition of excellence in supervision and mentoring, in 2015, he is an adjunct Professor in epigenetics at the Prince of Wales Hospital, Hong Kong as well as Honorary Associate, University College Copenhagen, Denmark. His highly original contributions are influential and reflected by prestigious international invitations that include keynote and plenary lectures, which in 2016 include EAS (Austria), EASD (Munich) and IDF-WPR (Taipei).

Since 2011, he has received >$6 Million dollars in external research funding, which has become more diversified to include not only NHMRC and Centre of Research Excellence funding but also competitive international sources such as the European Union and FP7 and JDRF. In 2009 he was awarded the prestigious Millennium Type 1 Diabetes Research Award by the Diabetes Australia Research Trust and received the inaugural Juvenile Diabetes Research Foundation & Macquarie Group Foundation for diabetes research innovation, in recognition excellence and innovation in medical research.

He has developed a training program for PhD students in the major technologies critical for contemporary epigenetic research and a major objective is his supervision of national and international scientists. As a recent Gordon Research Conference Chair, he continues to promote new scientific areas and contemporary themes. He serves on the editorial boards of several journals including Circulation Research, Epigenetics and Clinical Epigenetics and Epigenomics. As Chair for the Gordon Research Conference, he has organised the program for the first International Epigenomics of Diabetes meeting in 2018 and invited speaker to the GRC 2019-21meetings.

ASSAAD A. EID

As an academician, I am currently involved in internationally funded, cutting-edge basic, translational and clinical science research in the field of diabetes and diabetes-induced complications. Our research activities are part of advancing efforts to find novel treatments that aims to identifying a potential cure for the most recognized debilitating complications of diabetes. My research work focuses on identifying the cellular and molecular mechanisms leading to diabetes-induced complications specifically nephropathy and neuropathy, in order to design new therapeutic approaches to treat the onset and development of these complications. Our diabetes and diabetes-associated nephropathy and neuropathy research work ranges from the basic, translational  to the clinical aspects of the disease and combines a series of cellular, molecular, genetic and behavioral work approaches in cells, animal models of type 1  and type 2 diabetes and human tissues. 

As an academic entrepreneur, and in collaboration with multidisciplinary colleagues We founded 2 startups “Teucer Biotech” based in the United States of America and “eDiamond” that medical diagnostic tools for kidney diseases and biomedical devices for glucose monitoring respectively. Besides leading one of the highly funded research activities in Lebanon and the Middle East, I cofounded in 2017 the “AUB Diabetes” to integrate scientific and clinical  knowledge in order to enhance our understanding of the underlying pathologies of diabetes from both translational (bench to bedside) and clinical  perspectives. 

In recognition of my achievements in research and entrepreneurship through almost 70 peer reviewed publications and 3 patents, I was appointed in 2016  as Visiting Professor at Paris Descartes University, Paris, France and selected to join the International Diabetic Neuropathy Consortium and was appointed  as international collaborator in the Neuronetwork For Emerging Therapies at the University of Michigan at Ann Arbor. 

Likewise, in addition to several national and international scientific awards, I was selected as a member of the Inter-academy Medical Panel – Young  Physician Leaders and a young affiliate member of The World Academy of Sciences for the developing world. I also won the first prize in the startup  competitions of the Beirut International Healthcare Industry Forum. Recently, in February 2020, I was appointed as an advisor for the Presidency of the Council of Minister at Lebanon focusing on national research (scientific, medical industrial and environmental) and higher education.

PETER ROSSING

Professor Peter Rossing MD DMSc, 
Head of Complications Research, Chief Physician, 
Steno Diabetes Center Copenhagen, Denmark

Peter Rossing is a clinician researcher devoted to complications in diabetes with focus on renal and cardiovascular complications. He obtained a specialist degree in internal medicine and endocrinology 2004. Since 2007 he has been a chief physician and manager of the Steno Diabetes Center research team dedicated to the research of micro-and macrovascular complications of diabetes.

Since 2012 Professor in diabetic angiopathy at University of Copenhagen. Peter Rossing has in epidemiological studies investigated key features of the pathophysiology of the diabetic kidney at different stages. He has identified several markers for development of diabetic nephropathy; making it possible to predict the individual risk. He has been involved in several intervention studies in patients with overt diabetic nephropathy aiming at improving the prognosis.

He coordinated the EU FP7 project PRIORITY demonstrating that urinary proteomics can be used to stratify prevention of renal complications in type 2 diabetes, and the Novo Nordisk Foundation grant PROTON aiming at personalising prevention of diabetic nephropathy.

He has co-authored >480 papers and his h-index is 73. He received the Minkowski prize in 2005 and the Golgi prize in 2016 both from the EASD and the E. Bierman award from ADA. Past president of the Danish Endocrine Society, and of the European Diabetic Nephropathy Study group and chairman of the Danish National Diabetes Registry.

MY SVENSSON

My Svensson is a Professor in Nephrology at /University of Oslo/Akershus University Hospital and Head of the Research Department at Medical Division, Akershus University Hospital. Her main research area for almost 20 years has been the effects of marine n-3 fatty acids in patients with kidney disease. She has led several randomised controlled trials in the field, currently focusing on renal transplant recipients.

SUNNA SNAEDAL

A specialist of internal medicine and nephrology, consultant in Reykjavik, Iceland at the nephrology dpt of Landspitali University Hospital. PhD from CLINTEC, Karolinska Institutet, 2016 on inflammation and cardiovascular disease in the end stage kidney disease population. Is currently the head of the bioethics committee in Iceland.

VINCENT BRANDENBURG

Vincent Brandenburg is nephrologist and head of the department of Nephrology at the Rhein-Maas Klinikum in Würselen, Germany. His major clinical fields of interest are chronic kidney disease – mineral and bone disorder (CKD-MBD) including calciphylaxis, cardio-renal syndrome and cardiovascular disease associated with CKD.

Professor Brandenburg was associate professor and senior consultant at the Department of Cardiology, University Hospital of the RWTH Aachen, Germany until 2018. In this position he was Consultant for the Intermediate Care Unit and Heart Failure outpatient clinic. Prof. Brandenburg gained his medical degree in 1998 at the RWTH Aachen and the Ludwig-Maximilians University Munich, Germany. In 2005, he completed a two-years postdoctoral research period at the IZKF BioMAT, also at the University Hospital Aachen on the subject of the mechanism of extraosseous calcification in uremia. He then became a nephrologist at the Department of Nephrology, University Hospital Aachen (Head: Professor Jürgen Floege) until 2009 before he started completing his educational program in the cardiology department at the same institution. Professor Brandenburg has been conducting clinical research on the pathophysiology and treatment of renal osteodystrophy, bone disease after renal transplantation, and cardiovascular calcification in chronic kidney disease. His basic research interests are mechanisms of cardiovascular disease in uremia with particular focus upon vitamin K and oral anticoagulation. He has also conducted research about the role of alkaline phosphatase, PTH, fetuin-A, FGF23, cardiovascular effects of vitamin D and Wnt/beta-catenin signalling in the bone-vascular axis in uremia.

Vincent Brandenburg was also board member of the ERA-EDTA scientific working group “CKD-MBD” until 2017. A major research target is calciphylaxis. As such, he is currently leading the multinational European calciphylaxis registry “EuCalNet” for which he is principal investigator (www.calciphylaxis.net). Prof. Brandenburg was also principal investigator of several prospective human intervention trials investigating interventions against cardiovascular calcification progression. The clinical focus is the chronic cardio-renal syndrome. Dr Brandenburg has authored or co-authored over 200 articles in peer reviewed journals. He is member of the German and European societies of nephrology and the societies of cardiology. In 2018, he received the Nils-Alwall award from the German Society of Nephrology for his ongoing fight against calciphylaxis.

LISBET BRANDI

I was born in 1957. Educated as medical doctor i 1983 and as specialist in nephrology in 1999. I defended my doctoral thesis in 2008 regarding 1a(OH)D3 – Clinical studies of secondary hyperparathyroidism in uremic patients on chronic dialysis’. I got a master’s degree in leadership in 2007. Acutally I work as Chief Physician, Dept. of Cardiology, Nephrology and Endocrinology, Nordsjællands University Hospital.

From 1987 and onwards, my research activities have been focused on different nephrological clinical issues.The main focus has been on different aspects of Chronic Kidney Disease-Mineral Bone Disorder, oral phosphate binders, active vitamin D analogs and calcimimetics. In 2014 the research focus has turned a little bit from PTH and vitamin D in regulation of secondary hyperparathyroidism to also encompass the relationship between magnesium and vascular calcification in patients with chronic uremia.

I have published more than 45 peer reviewed papers and chapters in Danish medical text-books and patient information material. I have given oral and poster presentations at several medical conferences and lectures by invitation at national and international scientific meetings

I have been Principle Investigator and co-Investigator in several clinical intervention trials on most aspects of Chronic Kidney Disease (CDK). I have supervised PhD students of medical background, nurse and medical students for their master degree.

From 2014-2018 I was president of Danish Society of Nephrology, which includes a Board position in the research fund in the Danish Kidney Association for patients.

Through many years of collaboration an extensive and active network in the national and international scientific community within both basic and clinical research is gathered – across specialties, background education and training. Through common projects, many friendships and collaborations in industry and Danish universities are developed.

MATTHIAS KRETZLER

The overarching goal of my research is to define chronic kidney disease in mechanistic terms and use this knowledge for targeted therapeutic interventions.
To reach this goal my team has developed a translational research pipeline centered on integrated systems biology analysis of renal disease.
Our 25 years of experience in interdisciplinary data integration of large-scale data sets in international multi-disciplinary research networks in the US, Europe, China and sub-Saharan Africa enables precision medicine across the genotype-phenotype continuum.
We link carefully monitored environmental exposures, genetic predispositions, transcriptional networks, proteomic profiles, metabolic fingerprints, digital histological biopsy archive and prospective clinical disease characterization to define cross-cutting disease mechanisms. The molecular mechanism identified have result in more than 350 publications, but most importantly in new disease predictors, de novo drug development and successful clinical trials of novel therapeutic modalities in CKD, for details see MiKTMC.org.

JAAKKO PATRAKKA

I am a Consultant in Surgical Pathology and Adjunct Professor at Karolinska University Hospital. I defended my thesis at University of Helsinki nearly 20 years ago on newly discovered podocyte molecule nephrin. After that, I moved to Karolinska Institute and did my postdoctoral fellowship in prof. Karl Tryggvason´s laboratory, followed up by my clinical training and starting up my own research group. My research group applies cutting-edge molecular profiling methods to study basic biology and diseases of the glomerulus. We use various animal models, including mouse and zebrafish, to characterize molecular mechanisms driving the progression of chronic kidney disease. 

Astellas Pharma AB
Box 21046, 200 21 Malmö
Telefon 040-650 15 00
info.se@astellas.com
www.astellas.se

 Astellas Pharma
Vaisalantie 2–8, 02130 Espoo
Puhelin 09 8560 6000
info.fi@astellas.com
www.astellas.fi

Astellas Pharma a/s
Kajakvej 2, 2770 Kastrup
Telefon 4343 0355
kontakt.dk@astellas.com
www.astellas.dk

Astellas Pharma
Hagaløkkveien 26, 1385 Asker
Telefon 66 76 46 00
kontakt.no@astellas.com
www.astellas.no 

Astellas Pharma c/o Vistor hf.
Hörgatún 2, 210 Garðabær
Sími 535 7000
astellas@vistor.is
www.vistor.is

The sign up page is closed.

Please contact Jenny Wahlgren for information and/or late registration; jenny.wahlgren@astellas.com